Exact Sciences Corp. (EXAS) News
Filter EXAS News Items
EXAS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
EXAS News Highlights
- For EXAS, its 30 day story count is now at 8.
- Over the past 20 days, the trend for EXAS's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- CRC and VIEW are the most mentioned tickers in articles about EXAS.
Latest EXAS News From Around the Web
Below are the latest news stories about EXACT SCIENCES CORP that investors may wish to consider to help them evaluate EXAS as an investment opportunity.
Exact Sciences Corporation (NASDAQ:EXAS) Shares Could Be 31% Below Their Intrinsic Value EstimateKey Insights The projected fair value for Exact Sciences is US$107 based on 2 Stage Free Cash Flow to Equity Exact... |
Exact Sciences' (EXAS) Solid Cologuard Sales, Innovation AidFollowing the acquisitions of Paradigm and Ashion, Exact Sciences (EXAS) is offering therapy selection tests for patients with advanced cancer. |
1 Supercharged Growth Stock to Buy Before It Soars as Much as 222%, According to Cathie Wood's Ark InvestIf the fund manager's calculations prove to be correct, shareholders could enjoy threefold returns over the coming four years. Is she right? |
Ark Invest Stock Portfolio: 16 Biggest PositionsIn this article, we discuss the 16 biggest positions in the ARK Invest portfolio. If you want to read about some more stocks in the ARK Invest portfolio, go directly to Ark Invest Stock Portfolio: 5 Biggest Positions. Catherine D. Wood, although relatively new to the industry, stands out as a somewhat controversial hedge fund […] |
Here's Why You Should Retain Exact Sciences (EXAS) Stock NowInvestors are optimistic about Exact Sciences (EXAS) on strong Cologuard adoption and raised guidance. |
Better Growth Stock: Vertex Pharmaceuticals or Exact Sciences?Both of these biotech stocks have been market-beaters over the prior 10 years. One stock, however, is a better buy right now. |
Exact Sciences Awards Grants to 23 Organizations Focused on Increasing Colorectal Cancer ScreeningsExact Sciences, a leading provider of cancer screening and diagnostic tests, announced today that it awarded $1.3 million to 23 organizations through its Funding Opportunities for CRC Screening Uptake Strategies (FOCUS) Program. Grant recipients are committed to improving colorectal cancer (CRC) screening rates and making healthcare more accessible, with a focus on medically underserved populations. |
3 Stocks at the Forefront of Personalized Medicine TrendUnveiling the impact of personalized medicine stocks, transforming patient care, and propelling market growth seamlessly |
Exact Sciences (EXAS) Up 35.4% YTD: Will the Rally Continue?Investors are optimistic about Exact Sciences (EXAS), driven by growth in Screening and Precision Oncology segments. |
Why Is Exact Sciences (EXAS) Up 2.5% Since Last Earnings Report?Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |